Intravenous Immunoglobulin Market Summary
As per MRFR Analysis, the Intravenous Immunoglobulin (IVIG) Market was valued at 11.91 USD Billion in 2023 and is projected to grow to 19 USD Billion by 2035, with a CAGR of 3.96% from 2025 to 2035. The market is driven by the increasing prevalence of autoimmune diseases, rising awareness of IVIG therapy benefits, and advancements in manufacturing technologies. The demand for IVIG is also bolstered by its effectiveness in treating neurological disorders and infectious diseases, particularly in immunocompromised patients.
Key Market Trends & Highlights
The IVIG market is experiencing significant growth due to various trends.
- Market Size in 2024: 12.39 USD Billion; expected to reach 19 USD Billion by 2035.
- Immunodeficiency Disorders segment valued at 5.25 USD Billion in 2024; projected to rise to 8.53 USD Billion by 2035.
- Neurological Disorders segment valued at 3.12 USD Billion in 2024; anticipated to reach 4.89 USD Billion by 2035.
- North America market valued at 5.0 USD Billion in 2024; expected to grow to 8.0 USD Billion by 2035.
Market Size & Forecast
2023 Market Size: USD 11.91 Billion
2024 Market Size: USD 12.39 Billion
2035 Market Size: USD 19 Billion
CAGR (2025-2035): 3.96%
Largest Regional Market Share in 2024: North America.
Major Players
Key players include Takeda, Octapharma, CSL Behring, Kedrion, Grifols, and others.
Key Intravenous Immunoglobulin (IVIG) Market Trends Highlighted
The Intravenous Immunoglobulin (IVIG) Market is undergoing significant trends as a result of the increasing prevalence of autoimmune diseases and immunodeficiencies. More healthcare providers are now considering IVIG therapy as a viable treatment option due to the rising awareness of its benefits. Additionally, the quality and safety of IVIG products are being improved by advancements in manufacturing technologies, which is a substantial factor in the market's expansion.Â
Additionally, there is an increasing emphasis on personalized medicine, which has resulted in the development of IVIG therapies that are customized to the specific requirements of each patient, thereby enhancing the effectiveness of treatment.Â
Initiatives such as increasing investment in research and development can be implemented to capitalize on opportunities in the IVIG market. The healthcare infrastructure of developing countries is being progressively enhanced, resulting in an untapped market for IVIG therapies. Furthermore, the market's attractiveness could be improved by the development of innovative IVIG formulations and administration methods, which the growing collaborations among pharmaceutical companies, research institutions, and healthcare providers could facilitate.Â
There has been a recent trend toward the use of IVIG in off-label indications, which has expanded its therapeutic applications beyond its traditional uses. This change is motivated by the growing body of evidence that supports its efficacy in a variety of conditions, as well as ongoing clinical studies.Â
Additionally, there is a trend in the market toward patient-centric care, as healthcare systems are striving to offer more comprehensive treatment options that encompass IVIG.Consequently, the future landscape of the global IVIG market is anticipated to be significantly influenced by the current emphasis on enhancing the accessibility and affordability of IVIG therapies. 
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Intravenous Immunoglobulin (IVIG) Market Drivers
Increasing Incidence of Autoimmune Disorders
The Intravenous Immunoglobulin (IVIG) Market Industry is expected to experience significant growth due to the increasing prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. According to the World Health Organization (WHO), autoimmune diseases are among the top ten causes of death in females, and the incidence of these diseases is rising. The number of people affected by autoimmune diseases is estimated to increase by 3% annually, which highlights the growing need for therapies like Intravenous Immunoglobulin.
Furthermore, major healthcare organizations such as the American Autoimmune Related Diseases Association are also advocating for improved treatment options and better awareness of these conditions, which drives the demand for IVIG therapies globally.
Rising Popularity of IVIG in Neurological Disorders
The growing recognition of the effectiveness of Intravenous Immunoglobulin in treating neurological conditions is a key driver for the Intravenous Immunoglobulin (IVIG) Market Industry. Studies report that IVIG has shown positive results in treatments for disorders like Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The National Institute of Neurological Disorders and Stroke indicates that treatments for Guillain-Barré syndrome can lead to significant improvement in patient recovery, which has prompted a rise in the use of IVIG in clinical settings.
Consequently, increased investment by pharmaceutical companies in Research and Development (R) for neurological applications can enhance market growth and broaden treatment options.
Growing Demand for Immunoglobulin for Infectious Diseases
The rise in infectious diseases globally has significantly impacted the Intravenous Immunoglobulin (IVIG) Market Industry, as IVIG is regularly utilized to treat infections in immunocompromised patients. The Centers for Disease Control and Prevention (CDC) have reported a gradual increase in the incidence of infectious diseases such as hepatitis and cytomegalovirus (CMV). Furthermore, the COVID-19 pandemic has showcased the crucial role that immunoglobulin therapy can play in the treatment of viral infections.
This has prompted health authorities, including the World Health Organization (WHO), to recognize and recommend IVIG as an effective therapeutic option in combating such diseases, thereby increasing market demand significantly.
Intravenous Immunoglobulin (IVIG) Market Segment Insights
Intravenous Immunoglobulin (IVIG) Market Application InsightsÂ
The Intravenous Immunoglobulin (IVIG) Market has shown remarkable growth, particularly in the Application segment, which is critical in addressing various health challenges. In 2024, the overall market is set to be valued at 12.39 USD Billion, reflecting a strong demand across multiple applications.Â
Among these applications, Immunodeficiency Disorders hold a significant position, valued at 5.25 USD Billion in 2024 and projected to rise to 8.53 USD Billion by 2035. This dominant position underscores the importance of IVIG therapy in providing immune support for individuals with compromised immune systems.
Neurological Disorders also present substantial market potential, valued at 3.12 USD Billion in 2024 and anticipated to reach 4.89 USD Billion by 2035, highlighting the role of IVIG in treating conditions like Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. Autoimmune Disorders are valued at 2.75 USD Billion in 2024, with a projected increase to 4.34 USD Billion by 2035, demonstrating the growing reliance on IVIG therapy for managing diseases such as lupus and multiple sclerosis.Â
In contrast, the Infectious Diseases application segment shows a slight decline, valued at 1.27 USD Billion in 2024. It is expected to stabilize at 1.24 USD Billion by 2035, indicating its diminishing growth potential within the IVIG landscape.
The unique therapeutic properties of IVIG, including its ability to modulate immune responses and provide passive immunity, enhance its importance in treating Immunodeficiency Disorders and Neurological Disorders particularly. Overall, these market segments reflect significant revenue contributions and present opportunities for continued growth driven by research and development focused on enhancing existing therapies and addressing unmet medical needs in the Intravenous Immunoglobulin (IVIG) Market landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Intravenous Immunoglobulin (IVIG) Market End-Use Insights Â
The Intravenous Immunoglobulin (IVIG) Market shows a significant distribution across various End Use sectors, including Hospitals, Clinics, Homecare, and Pharmaceutical Companies. As of 2024, the overall market is valued at 12.39 USD Billion, poised for growth, reaching 19.0 USD Billion by 2035. Hospitals serve as a crucial point for IVIG treatments, given their resources and specialized staff, facilitating patient management for complex immunodeficiencies. Meanwhile, Clinics contribute to steady demand, mainly for patients requiring outpatient services, making them vital in the continuous care pathway.
The Homecare segment has gained momentum, driven by the trend towards patient-centric care models where infusion therapies are administered in a comfortable environment, reflecting a significant shift in healthcare paradigms. Pharmaceutical Companies play a key role in providing IVIG products, underscoring the importance of innovation and research within the industry, catering to growing global needs.Â
Overall, the Intravenous Immunoglobulin (IVIG) Market segmentation reflects an evolving landscape, adapting to patient demands and advancements in treatment approaches, with various segments experiencing unique growth drivers and challenges.
Intravenous Immunoglobulin (IVIG) Market Product Type Insights Â
The Intravenous Immunoglobulin (IVIG) Market is seeing substantial engagement in various product types, reflecting its essential role in treating immune deficiencies and other autoimmune diseases. With a market valuation expected to reach 12.39 USD Billion by 2024, the interest in this sector has been consistently growing. Among the product types, Intravenous Immunoglobulin holds significant importance, primarily due to its established efficacy in clinical applications and demand for treating multiple conditions.Â
The Subcutaneous Immunoglobulin type offers a convenient alternative for patients, thereby enhancing adherence to treatment regimens, which has propelled its adoption among healthcare practitioners and patients alike.
Combination therapies are also garnering attention as they represent strategic approaches to improve therapeutic outcomes, thereby playing a valuable role in addressing multifaceted health challenges. This segment's dynamics are fueled by trends such as increasing hospitalization rates and rising incidences of autoimmune disorders globally. Furthermore, the landscape presents opportunities led by advancements in manufacturing processes and the increasing availability of innovative immunoglobulin products. The anticipated growth in the Intravenous Immunoglobulin (IVIG) Market is reflective of these evolving trends and the necessity for effective immune treatments.
Intravenous Immunoglobulin (IVIG) Market Source Insights Â
The Intravenous Immunoglobulin (IVIG) Market is projected to reach a value of 12.39 billion USD by 2024, demonstrating a steady growth path in the industry. The Source segment within this market can be primarily categorized into Human Plasma and Recombinant Techniques. Human Plasma remains a vital source for IVIG production, providing essential antibodies that are crucial in treating various immunodeficiency disorders. The demand for Human Plasma has grown significantly due to its natural availability and effectiveness, thus playing a dominant role in the Intravenous Immunoglobulin (IVIG) Market.
On the other hand, Recombinant Techniques represent an innovative alternative, merging biotechnology with therapeutic development, offering more controlled and standardized products. This approach is gaining traction as it addresses challenges linked to plasma collection and supply issues. As the Intravenous Immunoglobulin (IVIG) Market looks forward, both sources will significantly impact the overall dynamics of market growth, regulatory considerations, and advancements in treatment methodologies for immunological diseases. The combination of these sources enhances the market's ability to cater to a diverse patient population, affirming the ongoing relevance of this segment.
Intravenous Immunoglobulin (IVIG) Market Regional Insights Â
The Intravenous Immunoglobulin (IVIG) Market exhibits significant regional segmentation, positioning North America as a dominant force with a market valuation of 5.0 USD Billion in 2024, anticipated to grow to 8.0 USD Billion by 2035. This region's majority holding can be attributed to advanced healthcare infrastructure and increasing applications in various chronic diseases. Europe follows closely, valued at 3.5 USD Billion in 2024 and expected to reach 5.5 USD Billion by 2035, benefiting from strong regulatory support and heightened awareness of immunoglobulin therapies.
The APAC region, valued at 2.5 USD Billion in 2024 and projected to be 3.5 USD Billion in 2035, is experiencing growth driven by rising patient population and increasing healthcare expenditure. Meanwhile, South America, with a valuation of 0.8 USD Billion in 2024 and MEA at 0.59 USD Billion, signals a developing market where increasing access to healthcare services is paving the way for future growth.Â
The Intravenous Immunoglobulin (IVIG) Market data reveals that North America and Europe continue to dominate due to robust healthcare frameworks. At the same time, APAC shows potential for significant expansion, considering the region's demographic advantages.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Intravenous Immunoglobulin (IVIG) Market Key Players and Competitive Insights
The Intravenous Immunoglobulin (IVIG) Market is characterized by its dynamic competitive landscape, driven by numerous factors such as technological advancements, regulatory changes, and evolving patient needs. The market is witnessing a steady increase in demand for immunoglobulin therapies due to the rising prevalence of primary immunodeficiency diseases and autoimmune disorders. Competitive insights reveal that companies are focusing on innovation and the development of new IVIG formulations to cater to diverse therapeutic areas.Â
Additionally, strategic collaborations, partnerships, and mergers are pivotal for companies aiming to enhance their market presence and expand their product offerings. The landscape is also shaped by the ongoing competition in terms of pricing, quality, and distribution channels, which emphasizes the importance of comprehensive market strategies to respond effectively to consumer demands and improve patient outcomes.
Takeda is recognized as a strong player in the Intravenous Immunoglobulin (IVIG) Market, leveraging its extensive experience and expertise in the biopharmaceutical sector. The company boasts a robust portfolio of immunoglobulin products, which has cemented its presence on a global scale.Â
Takeda's strengths lie in its commitment to research and development, enabling it to introduce innovative treatments that address unmet medical needs. The company stands out for its strong distribution network and strategic alliances that enhance its ability to deliver IVIG products effectively across various regions. Additionally, Takeda's emphasis on patient support programs aligns with its mission to improve the quality of life for patients suffering from immune deficiencies, further solidifying its position in the competitive landscape of the IVIG market.
Octapharma is another key competitor in the Intravenous Immunoglobulin (IVIG) Market, with a notable focus on plasma-derived therapies. The company offers a diverse range of IVIG products, which are designed to meet various clinical needs associated with immunotherapy. Octapharma's strengths include its advanced manufacturing capabilities and a commitment to maintaining high-quality standards in production. The company has expanded its market presence through strategic mergers and acquisitions, enabling it to enhance its product offerings and enter new markets more effectively.Â
Additionally, Octapharma emphasizes research and development, ensuring that it continues to innovate and improve its IVIG solutions in response to the evolving healthcare landscape. Their approach signifies a strong dedication to meeting patient requirements and driving growth within the global IVIG market.
Key Companies in the Intravenous Immunoglobulin (IVIG) Market Include
- Takeda
- Octapharma
- CSL Behring
- Kedrion
- Shenzhen Saierli
- Grifols
- Kangstem Biotech
- Salo Genetic
- Cambridge Antibody Technology
- ADMA Biologics
- Baxter
- Bharat Serums and Vaccines
- Emergent BioSolutions
- China Biologic Products
- LFB Group
Intravenous Immunoglobulin (IVIG) Market Industry Developments
Recent developments in the Intravenous Immunoglobulin (IVIG) Market indicate a growing trend in product demand and advancements in treatment applicability. Companies like Takeda and CSL Behring have noted significant investments in Research and Development to enhance the efficacy and delivery methods of IVIG therapies.Â
In September 2023, Takeda announced the expansion of their IVIG production facilities to meet rising global demand, particularly in North America and Europe. In August 2023, Grifols launched a new innovative formulation aimed at providing improved outcomes for patients with autoimmune disorders.Â
Acquisitions have also shaped the landscape, with Kedrion acquiring Merck’s IG business in July 2022 to strengthen its market position. Market growth is indicative of a broader increase in awareness regarding immune deficiencies, with countries globally adapting healthcare policies to facilitate better access to these treatments. Companies are observing improved market valuations, which correlate with the rise in IVIG therapy utilization for various clinical indications.
The Global market has seen a surge in investments, aiming to diversify product offerings and geographical outreach, fostering a competitive environment among key players such as Octapharma and China Biologic Products.
Intravenous Immunoglobulin (IVIG) Market Segmentation Insights
Intravenous Immunoglobulin (IVIG) Market Application Outlook
- Immunodeficiency Disorders
- Neurological Disorders
- Autoimmune Disorders
- Infectious Diseases
Intravenous Immunoglobulin (IVIG) Market End-Use Outlook
- Hospitals
- Clinics
- Homecare
- Pharmaceutical Companies
Intravenous Immunoglobulin (IVIG) Market Product Type Outlook
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Combination Therapies
Intravenous Immunoglobulin (IVIG) Market Source Outlook
- Human Plasma
- Recombinant Techniques
Intravenous Immunoglobulin (IVIG) Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
11.91(USD Billion)
|
|
Market Size 2024
|
12.39(USD Billion)
|
|
Market Size 2035
|
19.0(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
3.96% (2025 - 2035)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2035
|
|
Historical Data
|
2019 - 2024
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Takeda, Octapharma, CSL Behring, Kedrion, Shenzhen Saierli, Grifols, Kangstem Biotech, Salo Genetic, Cambridge Antibody Technology, ADMA Biologics, Baxter, Bharat Serums and Vaccines, Emergent BioSolutions, China Biologic Products, LFB Group
|
|
Segments Covered
|
Application, End Use, Product Type, Source, Regional
|
|
Key Market Opportunities
|
Increasing prevalence of autoimmune diseases, Expansion of product applications, Growth in geriatrics population, Rising demand for immunotherapy, Advancements in manufacturing technologies
|
|
Key Market Dynamics
|
Rising prevalence of autoimmune diseases, Growing geriatric population, Increasing awareness of IVIG benefits, Advancements in manufacturing technologies, High treatment costs, and reimbursement issues
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Intravenous Immunoglobulin Market Highlights:
Frequently Asked Questions (FAQ) :
The Intravenous Immunoglobulin (IVIG) Market is expected to be valued at 12.39 USD Billion in 2024.
By 2035, the Intravenous Immunoglobulin (IVIG) Market is projected to reach 19.0 USD Billion.
The expected compound annual growth rate (CAGR) for the Intravenous Immunoglobulin (IVIG) Market from 2025 to 2035 is 3.96%.
North America is expected to have the largest market share for Intravenous Immunoglobulin (IVIG) valued at 5.0 USD Billion in 2024.
The market size for the Intravenous Immunoglobulin (IVIG) Market in Europe is valued at 3.5 USD Billion in 2024.
In 2024, Immunodeficiency Disorders are valued at 5.25 USD Billion, Neurological Disorders at 3.12 USD Billion, Autoimmune Disorders at 2.75 USD Billion, and Infectious Diseases at 1.27 USD Billion.
One of the major players in the Intravenous Immunoglobulin (IVIG) Market is Takeda.
The market size for the APAC region in the Intravenous Immunoglobulin (IVIG) Market is projected to be 3.5 USD Billion by 2035.
By 2035, the market size for Autoimmune Disorders in the Intravenous Immunoglobulin (IVIG) Market is expected to reach 4.34 USD Billion.
The market size for Infectious Diseases is projected to decline slightly from 1.27 USD Billion in 2024 to 1.24 USD Billion in 2035
